Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.

Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA 3rd, Flaig TW, DeGraff DJ, Christensen E, Woolbright BL, McConkey DJ, Dyrskjøt L.

Nat Rev Urol. 2020 Mar 31. doi: 10.1038/s41585-020-0304-1. [Epub ahead of print] Review.

PMID:
32235944
2.

Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer.

Cooley LF, Glaser AP, Meeks JJ.

Urol Oncol. 2020 Feb 28. pii: S1078-1439(20)30041-7. doi: 10.1016/j.urolonc.2020.01.019. [Epub ahead of print] Review.

PMID:
32122728
3.

A simplified nomogram to assess risk of bladder cancer in patients with a new diagnosis of microscopic hematuria.

Matulewicz RS, Rademaker A, Meeks JJ.

Urol Oncol. 2020 Jan 14. pii: S1078-1439(19)30497-1. doi: 10.1016/j.urolonc.2019.12.010. [Epub ahead of print]

PMID:
31952999
4.

Willingness to Participate in Home Screening for Urologic Cancers in the General Population: An Online Survey of Over 1400 Adults.

Tsai KP, Hudnall MT, Weiner AB, Keeter MK, Meeks JJ.

Urology. 2020 Feb;136:35-40. doi: 10.1016/j.urology.2019.11.028. Epub 2019 Nov 30.

PMID:
31790787
5.

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.

Cooley LF, McLaughlin KA, Meeks JJ.

Urol Clin North Am. 2020 Feb;47(1):35-46. doi: 10.1016/j.ucl.2019.09.006. Review.

PMID:
31757298
6.

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ.

Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11.

PMID:
31712383
7.

Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines.

Rooney MK, Morgans AK, Chen RC, Golden DW, Meeks JJ, Auffenberg G, Kundu SD, Schaeffer EM, Hussain MH, Kalapurakal JA, Sachdev S.

Urology. 2020 Jan;135:1-3. doi: 10.1016/j.urology.2019.10.006. Epub 2019 Oct 24. No abstract available.

8.

Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study.

Weiner AB, Desai AS, Meeks JJ.

Eur Urol Oncol. 2019 May;2(3):304-310. doi: 10.1016/j.euo.2018.08.018. Epub 2018 Sep 14.

PMID:
31200845
9.

Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice?

Meeks JJ, McConkey DJ.

Eur Urol. 2019 Aug;76(2):207-208. doi: 10.1016/j.eururo.2019.05.025. Epub 2019 May 31. No abstract available.

PMID:
31155339
10.

Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?

VanderWeele DJ, Meeks JJ, Hussain M.

Transl Androl Urol. 2019 Mar;8(Suppl 1):S91-S92. doi: 10.21037/tau.2018.12.07. No abstract available.

11.

Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.

Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J.

J Urol. 2019 Aug;202(2):272-281. doi: 10.1097/JU.0000000000000318. Epub 2019 Jul 8.

PMID:
31059667
12.

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors.

Glaser AP, Procissi D, Yu Y, Meeks JJ.

J Vis Exp. 2019 Mar 29;(145). doi: 10.3791/59101.

PMID:
30985757
13.

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.

Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J, Getz G, Lerner SP.

Eur Urol. 2019 Jun;75(6):961-964. doi: 10.1016/j.eururo.2019.02.017. Epub 2019 Mar 7.

PMID:
30851984
14.

Disparities in the diagnostic evaluation of microhematuriaand implications for the detection of urologic malignancy.

Matulewicz RS, Demzik AL, DeLancey JO, Popescu O, Makarov DV, Meeks JJ.

Urol Oncol. 2019 May;37(5):300.e1-300.e7. doi: 10.1016/j.urolonc.2019.01.007. Epub 2019 Jan 18.

PMID:
30661870
15.

Automated Extraction of Grade, Stage, and Quality Information From Transurethral Resection of Bladder Tumor Pathology Reports Using Natural Language Processing.

Glaser AP, Jordan BJ, Cohen J, Desai A, Silberman P, Meeks JJ.

JCO Clin Cancer Inform. 2018 Dec;2:1-8. doi: 10.1200/CCI.17.00128.

16.

Contemporary Comparison of Open to Robotic Prostatectomy at a Veteran's Affairs Hospital.

Desai A, Hudnall M, Weiner AB, Patel M, Cohen J, Gogana P, Sharifi R, Meeks JJ.

Mil Med. 2019 May 1;184(5-6):e330-e337. doi: 10.1093/milmed/usy352.

PMID:
30535336
17.

Frequency of Testing for Prostate Cancer Using Prostate-Specific Antigen Among Older Men in a Large Health System.

Rowe TA, Lee JY, Meeks JJ, Persell SD.

Jt Comm J Qual Patient Saf. 2019 May;45(5):368-369. doi: 10.1016/j.jcjq.2018.10.003. Epub 2018 Nov 17. No abstract available.

PMID:
30455098
18.

Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients.

Fantini D, Seiler R, Meeks JJ.

Urol Oncol. 2019 Nov;37(11):818-825. doi: 10.1016/j.urolonc.2018.09.017. Epub 2018 Nov 13. Review.

PMID:
30446446
19.

Genomic classification and risk stratification of bladder cancer.

Fantini D, Meeks JJ.

World J Urol. 2019 Sep;37(9):1751-1757. doi: 10.1007/s00345-018-2558-2. Epub 2018 Nov 12. Review.

PMID:
30421072
20.

T1 bladder cancer: current considerations for diagnosis and management.

Jordan B, Meeks JJ.

Nat Rev Urol. 2019 Jan;16(1):23-34. doi: 10.1038/s41585-018-0105-y. Review.

PMID:
30323201
21.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
22.

Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research.

Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ.

Urol Oncol. 2019 May;37(5):313-317. doi: 10.1016/j.urolonc.2018.06.008. Epub 2018 Aug 13. Review.

23.

The BBN model: a mouse bladder cancer model featuring basal-subtype gene expression and MLL3/MLL4 genetic disruption.

Fantini D, Meeks JJ.

Oncoscience. 2018 Jun 29;5(5-6):172-173. doi: 10.18632/oncoscience.439. eCollection 2018 May. No abstract available.

24.

Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.

Wang L, Zhao Z, Ozark PA, Fantini D, Marshall SA, Rendleman EJ, Cozzolino KA, Louis N, He X, Morgan MA, Takahashi YH, Collings CK, Smith ER, Ntziachristos P, Savas JN, Zou L, Hashizume R, Meeks JJ, Shilatifard A.

Nat Med. 2018 Jun;24(6):758-769. doi: 10.1038/s41591-018-0034-6. Epub 2018 May 21.

25.

Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical Cystectomy.

Matulewicz RS, Patel M, Jordan BJ, Morano J, Frainey B, Bhanji Y, Bux M, Nader A, Kundu SD, Meeks JJ.

Bladder Cancer. 2018 Apr 26;4(2):161-167. doi: 10.3233/BLC-170157.

26.

Editorial Comment.

Meeks JJ, Glaser AP.

J Urol. 2018 Jul;200(1):60. doi: 10.1016/j.juro.2017.11.157. Epub 2018 Apr 19. No abstract available.

PMID:
29679580
27.

Rates and Predictors of Conversion to Open Surgery During Minimally Invasive Radical Cystectomy.

Ko OS, Weiner AB, Smith ND, Meeks JJ.

J Endourol. 2018 Jun;32(6):488-494. doi: 10.1089/end.2018.0079. Epub 2018 Apr 5.

PMID:
29620960
28.

Robotic-Assisted vs Laparoscopic Radical Nephrectomy.

Weiner AB, Matulewicz RS, Meeks JJ.

JAMA. 2018 Mar 20;319(11):1165. doi: 10.1001/jama.2017.21848. No abstract available.

PMID:
29558547
29.

Physician Perceptions of Patient Health: A Comparative Analysis between Urologist and Hospitalist Perceptions of Need for Inpatient Hospitalist Comanagement Following Radical Cystectomy.

Hannick JH, Adams W, Sandhu J, Kliethermes S, Mazur DJ, Meeks JJ, Sobek S, Coogan CL, Sadaf A, Quek ML, Schulwolf E.

Curr Urol. 2017 Nov;11(1):9-15. doi: 10.1159/000447188. Epub 2017 Nov 30.

30.

APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response.

Glaser AP, Fantini D, Wang Y, Yu Y, Rimar KJ, Podojil JR, Miller SD, Meeks JJ.

Oncotarget. 2017 Dec 16;9(4):4537-4548. doi: 10.18632/oncotarget.23344. eCollection 2018 Jan 12.

31.

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.

Dowling CM, Assel M, Musser JE, Meeks JJ, Sjoberg DD, Bosl G, Motzer R, Bajorin D, Feldman D, Carver BS, Sheinfeld J.

Urology. 2018 Apr;114:133-138. doi: 10.1016/j.urology.2018.01.014. Epub 2018 Feb 2.

32.

A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.

Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, Sze CC, Wang L, Zhao Z, Crawford SE, Hu D, Licht JD, Collings CK, Bartom E, Theodorescu D, Shilatifard A, Meeks JJ.

Oncogene. 2018 Apr;37(14):1911-1925. doi: 10.1038/s41388-017-0099-6. Epub 2018 Jan 25.

33.

Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the National Cancer Data Base (2004-2013).

Weiner AB, Keeter MK, Manjunath A, Meeks JJ.

Urol Oncol. 2018 May;36(5):237.e9-237.e17. doi: 10.1016/j.urolonc.2017.12.015. Epub 2018 Jan 12.

PMID:
29338913
34.

Molecular Landscape of Non-Muscle Invasive Bladder Cancer.

Meeks JJ, Lerner SP.

Cancer Cell. 2017 Nov 13;32(5):550-551. doi: 10.1016/j.ccell.2017.08.015.

35.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
36.

Reply by the Authors.

Oberlin DT, Catalona WJ, Meeks JJ.

Urology. 2017 Dec;110:267-268. doi: 10.1016/j.urology.2017.08.023. Epub 2017 Aug 25. No abstract available.

37.

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM.

J Oncol Pract. 2017 Sep;13(9):621-625. doi: 10.1200/JOP.2017.024919. Epub 2017 Aug 10. No abstract available.

PMID:
28796558
38.

Editorial Comment.

Matulewicz RS, Meeks JJ.

J Urol. 2017 Sep;198(3):519. doi: 10.1016/j.juro.2017.01.120. Epub 2017 May 30. No abstract available.

PMID:
28576555
39.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM.

J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26. Erratum in: J Urol. 2017 Nov;198(5):1175.

40.

Cystoscopy.

Matulewicz RS, DeLancey JO, Meeks JJ.

JAMA. 2017 Mar 21;317(11):1187. doi: 10.1001/jama.2017.0364. No abstract available.

PMID:
28324094
41.

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.

Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ.

Cancer. 2017 Jun 1;123(11):1912-1924. doi: 10.1002/cncr.30631. Epub 2017 Mar 21. Review.

42.

Robot-assisted retroperitoneal lymph node dissection (RA-RPLND) in the adolescent population.

Glaser AP, Bowen DK, Lindgren BW, Meeks JJ.

J Pediatr Urol. 2017 Apr;13(2):223-224. doi: 10.1016/j.jpurol.2017.01.007. Epub 2017 Feb 17.

PMID:
28262537
43.

The evolving genomic landscape of urothelial carcinoma.

Glaser AP, Fantini D, Shilatifard A, Schaeffer EM, Meeks JJ.

Nat Rev Urol. 2017 Feb 7;14(4):215-229. doi: 10.1038/nrurol.2017.11. [Epub ahead of print] Review.

PMID:
28169993
44.

Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer.

Matulewicz RS, DeLancey JO, Pavey E, Schaeffer EM, Popescu O, Meeks JJ.

Bladder Cancer. 2017 Jan 27;3(1):45-49. doi: 10.3233/BLC-160068.

45.

Bacillus Calmette-Guérin Manufacturing and SWOG S1602 Intergroup Clinical Trial.

Meeks JJ, Lerner SP, Svatek RS.

J Urol. 2017 Mar;197(3 Pt 1):538-540. doi: 10.1016/j.juro.2016.12.024. Epub 2016 Dec 16. No abstract available.

PMID:
27992750
46.

Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer.

Anderson BB, Oberlin DT, Razmaria AA, Choy B, Zagaja GP, Shalhav AL, Meeks JJ, Yang XJ, Paner GP, Eggener SE.

Eur Urol. 2017 Sep;72(3):455-460. doi: 10.1016/j.eururo.2016.11.028. Epub 2016 Dec 13.

PMID:
27986368
47.

Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer.

Oberlin DT, Casalino DD, Miller FH, Meeks JJ.

Abdom Radiol (NY). 2017 Apr;42(4):1255-1258. doi: 10.1007/s00261-016-0975-5.

PMID:
27858090
48.

High-Risk of Adverse Pathologic Features in Patients With Clinical T1 High-Grade Bladder Cancer Undergoing Radical Cystectomy.

Matulewicz RS, Frainey BT, Oberlin DT, Meeks JJ.

J Natl Compr Canc Netw. 2016 Nov;14(11):1403-1411. Epub 2016 Oct 31.

PMID:
27799511
49.

Editorial Comment.

Matulewicz RS, Meeks JJ.

J Urol. 2016 Nov;196(5):1421. doi: 10.1016/j.juro.2016.05.139. Epub 2016 Aug 19. No abstract available.

PMID:
27545337
50.

Genomic characterization of high-risk non-muscle invasive bladder cancer.

Meeks JJ, Carneiro BA, Pai SG, Oberlin DT, Rademaker A, Fedorchak K, Balasubramanian S, Elvin J, Beaubier N, Giles FJ.

Oncotarget. 2016 Nov 15;7(46):75176-75184. doi: 10.18632/oncotarget.12661.

Supplemental Content

Loading ...
Support Center